Contraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africa

Simple item page
dc.contributor.authorKibuuka, Hannah
dc.contributor.authorGuwatudde, David
dc.contributor.authorKimutai, Robert
dc.contributor.authorMaganga, Lucas
dc.contributor.authorMaboko, Leonard
dc.contributor.authorWatyema, Cecilia
dc.contributor.authorSawe, Fredrick
dc.contributor.authorShaffer, Douglas
dc.contributor.authorMatsiko, Dickson
dc.contributor.authorMillard, Monica
dc.contributor.authorMichael, Nelson
dc.contributor.authorWabwire-Mangen, Fred
dc.contributor.authorRobb, Merlin
dc.date.accessioned2022-02-05T12:15:27Z
dc.date.available2022-02-05T12:15:27Z
dc.date.issued2009
dc.description.abstractHIV vaccine trials generally require that pregnant women are excluded from participation, and contraceptive methods must be used to prevent pregnancy during the trial. However, access to quality services and misconceptions associated with contraceptive methods may impact on their effective use in developing countries. We describe the pattern of contraceptive use in a multi-site phase I/IIa HIV Vaccine trial in East Africa (Uganda, Kenya and Tanzania) and factors that may have influenced their use during the trial. Methods: Pregnancy prevention counseling was provided to female participants during informed consent process and at each study visit. Participants’ methods of contraception used were documented. Methods of contraceptives were provided on site. Pregnancy testing was done at designated visits during the trial. Obstacles to contraceptive use were identified and addressed at each visit. Results: Overall, 103 (31.8%) of a total of 324 enrolled volunteers were females. Female participants were generally young with a mean age of 29(67.2), married (49.5%) and had less than high school education (62.1%). Hormonal contraceptives were the most common method of contraception (58.3%) followed by condom use (22.3%). The distribution of methods of contraception among the three sites was similar except for more condom use and less abstinence in Uganda. The majority of women (85.4%) reported to contraceptive use prior to screening. The reasons for not using contraception included access to quality services, insufficient knowledge of certain methods, and misconceptions. Conclusion: Although hormonal contraceptives were frequently used by females participating in the vaccine trial, misconceptions and their incorrect use might have led to inconsistent use resulting in undesired pregnancies. The study underscores the need for an integrated approach to pregnancy prevention counseling during HIV vaccine trials.en_US
dc.identifier.citation: Kibuuka H, Guwatudde D, Kimutai R, Maganga L, Maboko L, et al. (2009) Contraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africa. PLoS ONE 4(4): e5164. doi:10.1371/journal.pone.0005164en_US
dc.identifier.other10.1371/journal.pone.0005164
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/1944
dc.language.isoenen_US
dc.publisherPLoS ONEen_US
dc.subjectContraceptive Useen_US
dc.subjectWomenen_US
dc.subjectHIV Vaccine Trialsen_US
dc.subjectEast Africaen_US
dc.titleContraceptive Use in Women Enrolled into Preventive HIV Vaccine Trials: Experience from a Phase I/II Trial in East Africaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Contraceptive Use in Women Enrolled into Preventive.pdf
Size:
82.33 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences